Liraglutide vs MOTS-c
Both Liraglutide and MOTS-c are used for metabolic. Here's how their evidence, dosing, and regulatory status actually compare.
Liraglutide
Evidence A+Liraglutide (Saxenda / Victoza)
The original once-daily GLP-1 receptor agonist. Lower weight-loss magnitude than semaglutide but a longer real-world track record across diabetes and obesity.
View full Liraglutide profile →MOTS-c
Evidence BMitochondrial-derived peptide MOTS-c
A 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.
View full MOTS-c profile →Side-by-Side
| Attribute | Liraglutide | MOTS-c |
|---|---|---|
| Evidence Grade | A+ | B |
| FDA Status | FDA-approved for weight management (Saxenda) and type 2 diabetes (Victoza) | Not FDA-approved — research peptide; multiple early-phase clinical trials |
| Typical Dose | 0.6–3.0 mg daily (subcutaneous) | 5–10 mg, 2–3 times weekly (subcutaneous) |
| Clinics Indexed | 540 | 22 |
| Categories | weight-loss, metabolic | metabolic, longevity |
Key reported benefits — Liraglutide
- ✓Weight loss
- ✓Appetite suppression
- ✓Glycemic control
Key reported benefits — MOTS-c
- ✓Insulin sensitivity
- ✓Exercise capacity
- ✓Metabolic flexibility
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.